The significant and growing global prevalence of diabetes continues to challenge people
with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Background Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …

Background: A composite metric for the quality of glycemia from continuous glucose monitor
(CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data …

Importance Declines in cardiovascular mortality have stagnated in the US over the past
decade, in part related to worsening risk factor control in older adults. Little is known about …

Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic β
cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced …

Diabetes mellitus is a chronic multifaceted disease with multiple potential complications, the
treatment of which can only delay and prolong the terminal stage of the disease, ie, type 2 …

Acute pancreatitis (AP) is an acute inflammation of the pancreas associated with high
morbidity and mortality. Endocrine pancreatic insufficiency secondary to AP has drawn …

Clinical studies on the treatment of type 1 diabetes with device-encapsulated pancreatic
precursor cells derived from human embryonic stem cells found that insulin output was …